Merck & CoNYSE: MRK

Angelica Peebles from CNBC shares updates about Merck.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck has declared its dividend for the first quarter of 2025.

The CHMP has given a favorable recommendation for the approval of MRK's Keytruda as a first-line treatment for malignant pleural mesothelioma.

In my newest article, I share forecasts for upcoming dividend increases from companies known for their long-term growth in dividends. I anticipate that 10 companies will reveal their annual increases in the latter part of November, with Merck expected to have small increases and Raymond James Financial likely to announce over a 10% increase. Additionally, Hormel Foods is set to declare its 59th consecutive year of dividend growth, showcasing its dedication to raising dividends.

MRK has obtained a bispecific antibody that works in the same way as SMMT's main drug, which did better than its popular drug, Keytruda, in a lung cancer trial.

Merck's shares are currently undervalued, priced at under four times the expected revenues for 2024, even with significant revenue growth from Keytruda and other medications. Keytruda's revenue is expected to rise by 70% between 2024 and 2032. Recent fluctuations in the stock price may be due to falling Gardasil sales in China and competition from Summit Therapeutics and Roche's Tecentriq.

Merck has reached a licensing deal valued at as much as $3.3 billion with LaNova Medicines, a company based in Shanghai, to create, produce, and market a new cancer treatment, the two firms announced on Thursday.

Lately, users of Zacks.com have been focusing on Merck (MRK). Therefore, it's important to take a look at what the stock might offer.

If you can be patient, these companies have many exciting projects planned for the future.